A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
暂无分享,去创建一个
K. Matthay | P. Adamson | R. Seeger | J. Eickhoff | M. Albertini | S. Gillies | R. Reisfeld | C. Reynolds | M. Krailo | J. Hank | P. Sondel | C. Twist | J. Gan | K. Osenga | Adam G. Sternberg | Adam Sternberg
[1] T. Warner,et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Gillies,et al. Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy , 2004, Clinical Cancer Research.
[3] C. Redfern,et al. Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2): Results of a Phase I Trial in Patients with Prostate Cancer , 2004, Journal of immunotherapy.
[4] M. Caligiuri,et al. What does it take to make a natural killer? , 2003, Nature Reviews Immunology.
[5] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[6] K. Matthay,et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Souhami,et al. Clinical Oncology, 2nd edn , 2000, British Journal of Cancer.
[8] S. Gillies,et al. Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins , 1999, Clinical Diagnostic Laboratory Immunology.
[9] M. Uttenreuther-Fischer,et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Dierckx,et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo , 1998, European Journal of Nuclear Medicine.
[11] R. Bechhofer,et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] N. Yuki,et al. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy , 1997, Journal of the Neurological Sciences.
[13] K. Matthay,et al. A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.
[14] L. Sorkin,et al. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody , 1997, Pain.
[15] J. Becker,et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. , 1996, The Journal of clinical investigation.
[16] R. Reisfeld,et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] K. Gough,et al. Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .
[18] R. Seeger,et al. Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[19] M. Rosenblum,et al. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study. , 1993, International journal of oncology.
[20] R. Bechhofer,et al. Serum CD25 Levels During Interleukin‐2 Therapy: Dose Dependence and Correlations with Clinical Toxicity and Lymphocyte Surface sCD25 Expression , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[21] R. R. Robinson,et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. , 1990, Cancer research.
[22] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[23] R. Bechhofer,et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. , 1988, Journal of the National Cancer Institute.
[24] R K Craig,et al. Methods in molecular medicine. , 1987, British medical journal.
[25] S. Rosenberg,et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.
[26] S. Rosenberg,et al. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. , 1987, Journal of immunology.
[27] K. Mujoo,et al. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. , 1987, Cancer research.
[28] KyungMann Kim,et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy , 2003, Cancer Immunology, Immunotherapy.
[29] S. Gillies,et al. Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine. , 2003, Methods in molecular medicine.
[30] S. Gillies,et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. , 1998, Blood.
[31] R. Reisfeld,et al. Antibody‐interleukin 2 fusion proteins: A new approach to cancer therapy , 1996, Journal of clinical laboratory analysis.
[32] M. Hanna. Tumor immunology and immunotherapy. , 1979, Advances in experimental medicine and biology.